“Medicine advances by studying new therapies to find out what works best in certain individuals. There is no value in studying drugs that are unlikely to be better than what is currently available, so when you participate in a phase 3 clinical trial, there’s a good chance you will benefit and little chance you will
be harmed,” says Cleveland Clinic’s Steven Nissen, MD, a world leader in conducting cardiovascular drug trials.
To continue reading this article or issue you must be a paid subscriber. Sign in Subscribe Subscribe to Heart Advisor Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge. Subscribe today and save 38%. It's like getting 5 months […]
To continue reading this article or issue you must be a paid subscriber. Sign in
